Maintaining a perfectly clean pool might not be the easiest of tasks, but the best robotic pool cleaners can significantly ease the process. These futuristic, autonomous machines efficiently ...

The typical cost to maintain a pool is $80 to $1,050, with a national average pool maintenance cost of $270. Maintenance frequency and type, in addition to pool size, type and material ...

“Ingots like this were used in the Viking world for trade,” said archaeologist Allison Fox of Manx National Heritage. Each ingot would have been weighed and tested to confirm its silver ...

Learn More › Many pool owners struggle with cloudy pool water at least once every swimming season. A few common causes of cloudy pool water include poor filtration or circulation, low levels of ...

These five archaeological sites comprise a system of monumental ring-shaped Viking-Age fortresses sharing a uniform geometric design. Constructed between about 970 and 980 CE, the fortresses at ...

Owning a house is a luxury, and owning one with a pool is even more so. Apart from being a fantastic way to keep cool during the hot summer months, pools provide a fun, outdoor place to entertain ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viking Therapeutics has been one of the hottest biopharma stocks in 2024. Even so, the market may be seriously underestimating the company's true value proposition. The lowdown is that VK2735 ...

Publisher Digital Eclipse and developer Crazy Viking Studios have announced side-scrolling action game Volgarr the Viking II for PlayStation 5, Xbox Series, PlayStation 4, Xbox One, Switch ...

Looking to cool down? It’s time to slap on Factor 50 and start packing that pool bag. If you’re planning a day of lounging then you’re in luck – as we’ve rounded up all the best pool day deals in ...

Viking Therapeutics (NASDAQ:VKTX) was a notable decliner among anti-obesity drug developers on Thursday after Swiss pharma giant Roche (OTCQX:RHHBY) said its dual GLP-1/GIP receptor agonist, CT ...